Strongbridge Biopharma Company Profile (NASDAQ:SBBP)

Analyst Ratings

Consensus Ratings for Strongbridge Biopharma (NASDAQ:SBBP) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $15.80 (257.47% upside)

Analysts' Ratings History for Strongbridge Biopharma (NASDAQ:SBBP)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2016Roth CapitalInitiated CoverageBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/10/2015Janney Montgomery ScottInitiated CoverageBuy$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/7/2015Stifel NicolausReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015JMP SecuritiesInitiated CoverageOutperform$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Strongbridge Biopharma (NASDAQ:SBBP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/17/2016        
5/17/2016Q1($0.63)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Strongbridge Biopharma (NASDAQ:SBBP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.31)($0.31)($0.31)
Q2 20161($0.51)($0.51)($0.51)
Q3 20161($0.47)($0.47)($0.47)
Q4 20161($0.38)($0.38)($0.38)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Strongbridge Biopharma (NASDAQ:SBBP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Strongbridge Biopharma (NASDAQ:SBBP)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Strongbridge Biopharma (NASDAQ:SBBP)
DateHeadline
07/06/16 06:51 AMStrongbridge Biopharma plc Announces Presentation at Cantor Fitzgerald’s 2nd Annual Healthcare Conference - [at noodls] - DUBLIN, Ireland and TREVOSE, Pa., July 06, 2016 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP), a global rare disease biopharmaceutical company focused on the development and commercialization ...
06/29/16 09:00 AMBig Moving Stocks Highlights Today – CCCL, RLOC, XNCR, CLWT, FUEL, ENDP, RNET
06/14/16 06:59 AMStrongbridge Biopharma plc to Participate in the JMP Securities Life Sciences Conference and 3rd Annual ROTH Healthcare Day in London - [at noodls] - DUBLIN, Ireland and TREVOSE, Pa., June 14, 2016 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP), a global rare disease biopharmaceutical company focused on the development and commercialization ...
06/09/16 03:39 PMStrongbridge Biopharma plc Announces Executive Promotion and Leadership Transition - [at noodls] - DUBLIN, Ireland and TREVOSE, Pa., June 09, 2016 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq:SBBP), a global rare disease biopharmaceutical company focused on the development and commercialization ...
06/08/16 05:08 PMStrongbridge Biopharma Plc :SBBP-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
06/02/16 03:15 PMStrongbridge Biopharma plc Announces Presentation at Jefferies 2016 Healthcare Conference - [at noodls] - DUBLIN, Ireland and TREVOSE, Pa., June 02, 2016 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP), a global rare disease biopharmaceutical company focused on the development and commercialization ...
06/02/16 07:25 AMEY Announces Strongbridge Biopharma's President and CEO Matthew Pauls is Named an EY Entrepreneur Of The Year® 2016 Finalist in Greater Philadelphia - [at noodls] - PHILADELPHIA, June 2, 2016 /PRNewswire/ -- EY today announced that Matthew Pauls, president and chief executive officer of Strongbridge Biopharma (NASDAQ: SBBP) is a finalist for the EY Entrepreneur Of ...
05/31/16 06:52 AMStrongbridge Biopharma plc Announces Presentation of COR-003 and COR-005 Data at the European Congress of Endocrinology - [at noodls] - DUBLIN, Ireland and TREVOSE, Pa., May 31, 2016 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq:SBBP), a global rare disease biopharmaceutical company focused on the development and commercialization ...
05/17/16 07:52 AMStrongbridge Biopharma plc Reports First Quarter 2016 Financial Results - [at noodls] - DUBLIN and TREVOSE, Pa., May 17, 2016 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq:SBBP), a global rare disease biopharmaceutical company focused on the development and commercialization of novel ...
05/17/16 07:42 AMStrongbridge Biopharma reports 1Q loss -
05/05/16 08:21 AMStrongbridge Biopharma plc Announces Presentation at Bio€quity Europe 2016 - [at noodls] - DUBLIN and TREVOSE, Pa., May 05, 2016 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP), a global rare disease biopharmaceutical company focused on the development and commercialization of novel ...
04/25/16 06:09 AMCoverage initiated on Strongbridge Biopharma by H.C. Wainwright -
04/13/16 09:55 AMWhat’s Buzzing: Stock Gaps Up – LBTYB, SBBP, KOOL, LEU, CSTE, HLX, FOLD, HPJ, CHK, OBCI - The company traded at $40.21 + 8.87 (28.30 percent). Strongbridge Biopharma plc (SBBP) posted a gap up of 0.39 pts or 9.05 percent above its previous close of $4.31. The company traded at $4.78 + 0.47 (10.90 percent). Cesca Therapeutics Inc (KOOL ...
04/06/16 06:50 AMStrongbridge Biopharma plc Announces Presentation at 15th Annual Needham Healthcare Conference - [at noodls] - DUBLIN, Ireland and TREVOSE, Pa., April 06, 2016 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc(NASDAQ:SBBP), a global rare disease biopharmaceutical company focused on the development and commercialization ...
04/04/16 09:23 AMThese Wall Street Stocks are Gapping Up today… - The company traded at $2.01 + 0.1999 (11.04 percent). Strongbridge Biopharma plc (SBBP) had a gap up of 0.2499 pts or 5.48 percent above its previous close of $4.56. The company traded at $5.16 + 0.5962 (13.07 percent). Asta Funding Inc. (ASFI ...
04/04/16 09:23 AMStrongbridge Biopharma Plc Announces Presentation Of COR-003 Data At The Endocrine Society's 2016 Annual Conference - DUBLIN, Ireland and TREVOSE, Pa., April 04, 2016 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq:SBBP), a global rare disease biopharmaceutical company focused on the development and commercialization of novel therapeutic options, today announced ...
04/04/16 06:57 AMStrongbridge Biopharma plc Announces Presentation of COR-003 Data at the Endocrine Society’s 2016 Annual Conference - [at noodls] - DUBLIN, Ireland and TREVOSE, Pa., April 04, 2016 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq:SBBP), a global rare disease biopharmaceutical company focused on the development and commercialization ...
03/30/16 12:04 PMSTRONGBRIDGE BIOPHARMA PLC Financials -
03/24/16 06:56 AMStrongbridge Biopharma plc Reports Full-Year 2015 Financial Results - [at noodls] - DUBLIN, Ireland and TREVOSE, Pa., March 24, 2016 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq:SBBP), a global rare disease biopharmaceutical company focused on the development and commercialization ...
03/22/16 09:15 AMStocks Making Gaps Up today – FORK, STAF, SBBP, PNRG, SMLR, TGEN, DRIO - The company traded at $2.63 + 0.2442 (10.22 pct). Strongbridge Biopharma plc (SBBP) had a gap up of 0.2999 pts or 7.14 pct above its previous close of $4.20. The company traded at $4.85 + 0.6499 (15.47 pct). PrimeEnergy Corporation (PNRG) had a gap up of 5 ...
03/10/16 08:52 AMActive Stocks Rising – SBBP, URRE, XNCR, THO, UNFI, OMER, LEU, SCTY, URBN, SUNE - Strongbridge Biopharma plc (SBBP) traded at $5.50 + 1.01 (22.49 pct). The company is +45.16 pct in the last four weeks, -27.63 pct year-to-date, and — during the past four quarters. Uranium Resources Inc (URRE) traded at $2.39 + 2.14 (855.62 pct).
03/09/16 08:39 AMBiggest Moving Stocks, March 9 – URRE, OMER, OTEL, URBN, SBBP, SCTY, AMSC, EPIX, TERP - The company is +39.52 pct year-to-date, and -19.32 pct during the past four quarters. Strongbridge Biopharma plc (SBBP) traded at $4.99 + 0.50 (11.14 pct) on 6,034 total stock volume. The company is -34.34 pct year-to-date, and — during the past four ...
03/07/16 09:55 AMBucks biopharm firm returns one drug candidate, stops development of another -
03/07/16 06:33 AM7:33 am Strongbridge Biopharma provides update on corporate progress; co initiates the return of COR-004 to Antisense Therapeutics and will not invest further in the development of BP-2002 -
02/25/16 06:30 AMStrongbridge Biopharma plc Announces Presentations at Two Upcoming Investor Conferences - [GlobeNewswire] - DUBLIN, Ireland and TREVOSE, Pa., Feb. 25, 2016-- Strongbridge Biopharma plc today announced that Matthew Pauls, president and chief executive officer, is scheduled to present a corporate overview at two ...
02/24/16 08:31 AMTraders Pick These Stocks Today – Strongbridge (SBBP), Aclaris (ACRS), Check-Cap (CHEK) - Strongbridge Biopharma plc (SBBP) traded at $4.55 + 0.3899 (9.37 percent). The company is -8.57 percent during the past four weeks, -40.13 percent year to date, and — in the past four quarters. Aclaris Therapeutics Inc (ACRS) traded at $18.64 + 1.88 ...
02/22/16 07:57 AMManufacturing Sector’s Top Gainers and Losers, Feb. 22 - Continental Materials Corp (CUO)- The company’s shares dropped 9.37 pct. Strongbridge Biopharma Plc (SBBP)- The company’s shares declined 11.08 pct. Steadymed Ltd (STDY)- The company’s stocks retreated 5.17 pct. Valeant Pharmaceuticals International ...
02/18/16 03:05 PMStrongbridge Biopharma Announces Annual General Meeting of Shareholders - [GlobeNewswire] - DUBLIN, Ireland and TREVOSE, Pa., Feb. 18, 2016-- Strongbridge Biopharma plc today announced that the Company will hold its Annual General Meeting of Shareholders on Thursday, May 12, 2016 at the offices ...
02/18/16 06:30 AMStrongbridge Biopharma plc Announces Participation at SunTrust Robinson Humphrey’s 2016 Orphan Drug Day - [GlobeNewswire] - DUBLIN, Ireland and TREVOSE, Pa., Feb. 18, 2016-- Strongbridge Biopharma plc today announced that management will be attending SunTrust Robinson Humphrey’ s 2016 Orphan Drug Day on February 23, 2016 in ...
01/24/16 07:45 AMStrongbridge Biopharma plc (SBBP) - Strongbridge Biopharma plc, a biopharmaceutical company, through its subsidiary, Cortendo AB (publ), develops, acquires, and commercializes product candidates that target rare diseases. The company s lead product candidate, COR-003 (levoketoconazole), is ...
12/16/15 06:56 AMStrongbridge Biopharma plc Announces Presentation at Biotech Showcase 2016 - [at noodls] - and , (GLOBE NEWSWIRE) -- (NASDAQ:SBBP) today announced that management will be presenting at Biotech Showcase 2016 to be held in . , president and chief executive officer of , is scheduled to present ...
12/07/15 06:52 AMStrongbridge Biopharma Announces Issuance of U.S. Patent for Investigational COR-003 (levoketoconazole) in Treatment of Endogenous Cushing's Syndrome - [at noodls] - DUBLIN, Ireland and TREVOSE, Pa., Dec. 7, 2015 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq:SBBP) today announced that the United States Patent and Trademark Office (USPTO) issued a patent related ...
12/01/15 06:43 AMStrongbridge Biopharma plc Announces Presentation at the 26th Annual Oppenheimer Healthcare Conference - [at noodls] - DUBLIN, Ireland and TREVOSE, Pa., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) today announced that management will be presenting at the 26th Annual Oppenheimer Healthcare ...
11/30/15 07:40 AMNew Information Reveals Opportunity in Volatility - Research on Strongbridge Biopharma, Pacific Mercantile Bancorp, Codexis and Exa Corp - [Accesswire] - NEW YORK, NY / ACCESSWIRE / November 30, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Strongbridge ...
11/23/15 06:45 AMStrongbridge Biopharma plc Announces Presentation at Arctic Biotech Seminar - [at noodls] - DUBLIN, Ireland and TREVOSE, Pa., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) today announced that management will be presenting at the Arctic Biotech Seminar in Oslo, Norway. ...
11/18/15 07:55 AMStrongbridge Biopharma plc Provides Update on Corporate Progress - [at noodls] - Strongbridge Advances Clinical Development of Rare Endocrine Disease Portfolio With COR-003, COR-004 and COR-005 Strongbridge Expands Key Functional Area Expertise With Senior Hires Strongbridge Provides ...
11/04/15 06:30 AMStrongbridge Biopharma plc Announces Presentation at the Stifel 2015 Healthcare Conference - [GlobeNewswire] - DUBLIN, Ireland and TREVOSE, Pa. -- Strongbridge Biopharma plc (NASDAQ:SBBP) today announced that management will be presenting at the Stifel 2015 Healthcare Conference to be held November 17 -- 18, 2015 ...
11/03/15 07:47 PMATL1103: Data Presentation at the Society for Endocrinology BES 2015 Conference - [at noodls] - Microsoft Word - ASX 15_ 4 November 2015.docx 4 November 2015 Antisense Therapeutics Limited ('ANP' or the 'Company') wishes to advise that its licensing partner of ATL1103 (Strongbridge Biopharma) announced ...
11/03/15 06:56 AMStrongbridge Biopharma plc Announces Data Presentation at the Society for Endocrinology BES 2015 Conference - [at noodls] - Secondary Analysis From Phase 2 Study Supports Novel Mechanism of Action of COR-004 to Reduce IGF-1 in Patients With Acromegaly by Inhibiting Growth Hormone Receptor (GHR) Expression DUBLIN, Ireland and ...
11/02/15 07:00 AMMast Therapeutics Announces Appointment Of Matthew Pauls To Board Of Directors - [PR Newswire] - SAN DIEGO, Nov. 2, 2015 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, today announced that Matthew Pauls has been appointed to the Company's Board of Directors, effective immediately. Mr. Pauls brings more than 20 years of experience in the pharmaceutical industry, including senior leadership roles in a broad spectrum of operational areas and significant experience in new product launches, commercial and technical operations, as well as clinical development, with a specific focus on orphan drug candidates.
10/18/15 08:29 AMFerrari Leads IPO Calendar for Week of October 19 -

Social

About Strongbridge Biopharma

Strongbridge Biopharma logoStrongbridge Biopharma plc, formerly Cortendo plc, is a development-stage biopharmaceutical company. The Company is engaged in advancing its product candidates through clinical development. The Company is focused on the development, in-licensing, acquisition and eventual commercialization of several complementary products and product candidates within franchises that target rare diseases. Its principal focus is to build its rare endocrine franchise, which includes product candidates for the treatment of endogenous Cushing's syndrome and acromegaly. Its product candidate, COR-003 (levoketoconazole), is a cortisol synthesis inhibitor, indicated for the treatment of endogenous Cushing's syndrome. It is conducting SONICS, a pivotal Phase III clinical trial for COR-003. Its product candidate, COR-005 (veldotide), is a multi-receptor targeted somatostatin analog (SSA) in Phase II clinical development for the treatment of acromegaly patients. Its product candidate also includes BP-2002.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SBBP
  • CUSIP:
Key Metrics:
  • Previous Close: $4.42
  • 50 Day Moving Average: $4.10
  • 200 Day Moving Average: $4.54
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $93.73M
  • Current Year EPS Consensus Estimate: $-1.78 EPS
  • Next Year EPS Consensus Estimate: $-1.26 EPS
Additional Links:
Strongbridge Biopharma (NASDAQ:SBBP) Chart for Sunday, July, 24, 2016